Neos Therapeutics (NASDAQ: NEOS) is one of 112 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare Neos Therapeutics to similar businesses based on the strength of its analyst recommendations, earnings, valuation, dividends, risk, institutional ownership and profitability.
This table compares Neos Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Neos Therapeutics Competitors||-3,613.24%||-54.73%||-9.09%|
Institutional & Insider Ownership
44.3% of Neos Therapeutics shares are held by institutional investors. Comparatively, 43.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 5.2% of Neos Therapeutics shares are held by company insiders. Comparatively, 12.1% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Volatility & Risk
Neos Therapeutics has a beta of -0.9, indicating that its stock price is 190% less volatile than the S&P 500. Comparatively, Neos Therapeutics’ peers have a beta of 0.86, indicating that their average stock price is 14% less volatile than the S&P 500.
This is a summary of recent recommendations and price targets for Neos Therapeutics and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Neos Therapeutics Competitors||944||3794||6012||164||2.49|
Neos Therapeutics presently has a consensus price target of $16.75, suggesting a potential upside of 87.15%. As a group, “Pharmaceuticals” companies have a potential upside of 27.44%. Given Neos Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Neos Therapeutics is more favorable than its peers.
Earnings and Valuation
This table compares Neos Therapeutics and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Neos Therapeutics||$15.62 million||-$69.70 million||-2.01|
|Neos Therapeutics Competitors||$7.78 billion||$2.46 billion||0.90|
Neos Therapeutics’ peers have higher revenue and earnings than Neos Therapeutics. Neos Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Neos Therapeutics peers beat Neos Therapeutics on 7 of the 12 factors compared.
Neos Therapeutics Company Profile
Neos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). Its product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. Its branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. Its modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications. It focuses on developing Adzenys XR-ODT, Cotempla XR-ODT and NT-0201.
Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.